Initiator Pharma ready to start Phase I pharmacokinetics study for new IP2015 formulations

Initiator Pharma A/S, a clinical-stage pharma company, announced today that it will initiate a Phase I pharmacokinetic study in healthy subects evaluating new oral solid dosage forms enabling a bridging between previous data sets into new future clinical studies for IP2015.

The Phase I study will be an open labelled randomized study in 12 healthy subjects evaluating current and new oral solid dosage formulations of IP2015. It was approved by the British Regularotory Authorities, MHRA and the Ethics Committee and is expected to start in the beginning of 2023 and provide draft phamacokinetic data in Q2 2023. The study will also strengthen the intellectual property rights (IPR) portfolio for the entire IP2015 program.

"I am pleased with the approval of the Phase I pharmacokinetics study and look forward to getting started after the holidays. This study is vital in designing and executing future clinical development studies for IP2015. Furthermore, the solid dosage formulation brings us closer to having a final drug product that may be used in a potential future launch," says Claus Elsborg Olesen, CEO at Initiator Pharma.

For additional information about Initiator Pharma, please contact:

Claus Elsborg Olesen, CEO
Telephone: +45 6126 0035
E-mail: **ceo@initiatorpharma.com**

About Initiator Pharma

Initiator Pharma A/S is a Danish clinical stage life science company developing innovative drugs that target key unmet medical needs within the central and peripheral nervous system. Initiator Pharma' s pipeline consists of three clinical programs - the drug candidates IP2018 and IPED2015 for treatment of erectile dysfunction of psychogenic and organic origin, respectively, and the orphan drug candidate IPTN2021 developed for Trigeminal Neuralgia, a severe neuropathic pain condition.

Initiator Pharma is listed on Nasdaq First North Growth Market (ticker: INIT). Redeye AB is the company's Certified Adviser. For more information, please visit **www.initiatorpharma.com.**

Attachments

Initiator Pharma ready to start Phase I pharmacokinetics study for new IP2015 formulations